Global partnerships to help customers improve clinical and commercial efficiency and effectiveness<\/i><\/p>\n
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif. \u2014 August 18, 2025 \u2014 <\/strong> IQVIA<\/a> (NYSE: IQV) and ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from ³Ô¹Ï±¬ÁÏ and IQVIA together in a simple and efficient way.<\/p>\n \nThe global partnerships make it easy for customers to work with IQVIA and ³Ô¹Ï±¬ÁÏ in key areas including:\n<\/p>\n \n\u201cWe are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall,\u201d said ³Ô¹Ï±¬ÁÏ founder and CEO Peter Gassner. \u201cI am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers.\u201d\n<\/p>\n \n\u201cIQVIA and ³Ô¹Ï±¬ÁÏ\u2019s partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients,\u201d said Ari Bousbib, chairman and CEO of IQVIA. \u201cThis will enable IQVIA customers on ³Ô¹Ï±¬ÁÏ platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients.\u201d\n<\/p>\n \nFor more information visit ³Ô¹Ï±¬ÁÏ Partnerships<\/a> on iqvia.com or IQVIA Partnerships<\/a> on veeva.com.\n<\/p>\n \nAbout IQVIA<\/strong> \nIQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA\u2019s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com<\/a>.\n<\/p>\n \nAbout ³Ô¹Ï±¬ÁÏ Systems<\/strong> \n³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong> ###<\/p>\n <\/center><\/p>\n Contacts:<\/strong> <\/p>\n \n\t\tMaria Scurry \n\t\tGunnar Hansen \n\t\tAlissa Maupin\n
\nIQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA\u2019s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI\u00ae, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.\n<\/p>\n
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com<\/a>.\n<\/p>\n
\nThis release contains forward-looking statements regarding the expected results and benefits from ³Ô¹Ï±¬ÁÏ’s partnerships with IQVIA. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements.\n<\/p>\n
\n\t\t³Ô¹Ï±¬ÁÏ Media Relations
\n\t\t781-366-7617
\n\t\tmaria.scurry@veeva.com<\/a>\n\t\t<\/p>\n
\n\t\t³Ô¹Ï±¬ÁÏ Investor Relations
\n\t\t267-460-5839
\n\t\tgunnar.hansen@veeva.com<\/a>\n\t\t<\/p>\n<\/p><\/div>\n
\n\t\tIQVIA Media Relations
\n\t\t919-923-6785
\n\t\talissa.maupin1@iqvia.com<\/a>\n\t\t<\/p>\n